Three emerging new drugs for NSCLC

Pemetrexed, bortezomib, and cetuximab

Sarita Dubey, Joan H. Schiller

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Despite advances made in cytotoxic chemotherapy, the prognosis for patients with non-small cell lung cancer (NSCLC) continues to be poor. New, more effective drugs must be identified and developed to improve the outcome of these patients. Three drugs with promising activity in NSCLC are pemetrexed (Alimta®; Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com), bortezomib (Velcade®; Millennium Pharmaceuticals, Inc., Cambridge, MA, http://www.mlnm.com), and cetuximab (Erbitux®; ImClone Systems, Inc., New York, NY, http://www.imclone.com). Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, enzymes necessary for purine and pyrimidine synthesis, thus causing cell-cycle arrest in the S phase. Bortezomib, a proteasome inhibitor, interferes with the cytosolic protein degradation machinery, namely the ubiquitin-proteasome complex, causing breakdown of cell-cycle regulators and cell-cycle arrest. Cetuximab is a chimeric mouse-human antibody that inhibits ligand-dependent activation of the epidermal growth factor receptor, resulting in receptor internalization and inhibition of downstream pathways that, in turn, causes cell growth and progression. All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way.

Original languageEnglish (US)
Pages (from-to)282-291
Number of pages10
JournalOncologist
Volume10
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Pemetrexed
Non-Small Cell Lung Carcinoma
Cell Cycle Checkpoints
Pharmaceutical Preparations
Hydroxymethyl and Formyl Transferases
Proteasome Inhibitors
Proteasome Endopeptidase Complex
Ubiquitin
S Phase
Epidermal Growth Factor Receptor
Proteolysis
Cell Cycle
Ligands
Drug Therapy
Bortezomib
Cetuximab
Antibodies
Enzymes
Growth
Neoplasms

Keywords

  • Bortezomib
  • Cetuximab
  • Lung cancer
  • Pemetrexed

ASJC Scopus subject areas

  • Cancer Research
  • Hematology

Cite this

Three emerging new drugs for NSCLC : Pemetrexed, bortezomib, and cetuximab. / Dubey, Sarita; Schiller, Joan H.

In: Oncologist, Vol. 10, No. 4, 04.2005, p. 282-291.

Research output: Contribution to journalArticle

Dubey, Sarita ; Schiller, Joan H. / Three emerging new drugs for NSCLC : Pemetrexed, bortezomib, and cetuximab. In: Oncologist. 2005 ; Vol. 10, No. 4. pp. 282-291.
@article{c235194a56b64729961761ff83f79c60,
title = "Three emerging new drugs for NSCLC: Pemetrexed, bortezomib, and cetuximab",
abstract = "Despite advances made in cytotoxic chemotherapy, the prognosis for patients with non-small cell lung cancer (NSCLC) continues to be poor. New, more effective drugs must be identified and developed to improve the outcome of these patients. Three drugs with promising activity in NSCLC are pemetrexed (Alimta{\circledR}; Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com), bortezomib (Velcade{\circledR}; Millennium Pharmaceuticals, Inc., Cambridge, MA, http://www.mlnm.com), and cetuximab (Erbitux{\circledR}; ImClone Systems, Inc., New York, NY, http://www.imclone.com). Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, enzymes necessary for purine and pyrimidine synthesis, thus causing cell-cycle arrest in the S phase. Bortezomib, a proteasome inhibitor, interferes with the cytosolic protein degradation machinery, namely the ubiquitin-proteasome complex, causing breakdown of cell-cycle regulators and cell-cycle arrest. Cetuximab is a chimeric mouse-human antibody that inhibits ligand-dependent activation of the epidermal growth factor receptor, resulting in receptor internalization and inhibition of downstream pathways that, in turn, causes cell growth and progression. All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way.",
keywords = "Bortezomib, Cetuximab, Lung cancer, Pemetrexed",
author = "Sarita Dubey and Schiller, {Joan H.}",
year = "2005",
month = "4",
doi = "10.1634/theoncologist.10-4-282",
language = "English (US)",
volume = "10",
pages = "282--291",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "4",

}

TY - JOUR

T1 - Three emerging new drugs for NSCLC

T2 - Pemetrexed, bortezomib, and cetuximab

AU - Dubey, Sarita

AU - Schiller, Joan H.

PY - 2005/4

Y1 - 2005/4

N2 - Despite advances made in cytotoxic chemotherapy, the prognosis for patients with non-small cell lung cancer (NSCLC) continues to be poor. New, more effective drugs must be identified and developed to improve the outcome of these patients. Three drugs with promising activity in NSCLC are pemetrexed (Alimta®; Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com), bortezomib (Velcade®; Millennium Pharmaceuticals, Inc., Cambridge, MA, http://www.mlnm.com), and cetuximab (Erbitux®; ImClone Systems, Inc., New York, NY, http://www.imclone.com). Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, enzymes necessary for purine and pyrimidine synthesis, thus causing cell-cycle arrest in the S phase. Bortezomib, a proteasome inhibitor, interferes with the cytosolic protein degradation machinery, namely the ubiquitin-proteasome complex, causing breakdown of cell-cycle regulators and cell-cycle arrest. Cetuximab is a chimeric mouse-human antibody that inhibits ligand-dependent activation of the epidermal growth factor receptor, resulting in receptor internalization and inhibition of downstream pathways that, in turn, causes cell growth and progression. All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way.

AB - Despite advances made in cytotoxic chemotherapy, the prognosis for patients with non-small cell lung cancer (NSCLC) continues to be poor. New, more effective drugs must be identified and developed to improve the outcome of these patients. Three drugs with promising activity in NSCLC are pemetrexed (Alimta®; Eli Lilly and Company, Indianapolis, IN, http://www.lilly.com), bortezomib (Velcade®; Millennium Pharmaceuticals, Inc., Cambridge, MA, http://www.mlnm.com), and cetuximab (Erbitux®; ImClone Systems, Inc., New York, NY, http://www.imclone.com). Pemetrexed inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase, enzymes necessary for purine and pyrimidine synthesis, thus causing cell-cycle arrest in the S phase. Bortezomib, a proteasome inhibitor, interferes with the cytosolic protein degradation machinery, namely the ubiquitin-proteasome complex, causing breakdown of cell-cycle regulators and cell-cycle arrest. Cetuximab is a chimeric mouse-human antibody that inhibits ligand-dependent activation of the epidermal growth factor receptor, resulting in receptor internalization and inhibition of downstream pathways that, in turn, causes cell growth and progression. All three drugs are approved for different tumor types, and studies defining their role in NSCLC are under way.

KW - Bortezomib

KW - Cetuximab

KW - Lung cancer

KW - Pemetrexed

UR - http://www.scopus.com/inward/record.url?scp=17644383708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644383708&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.10-4-282

DO - 10.1634/theoncologist.10-4-282

M3 - Article

VL - 10

SP - 282

EP - 291

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 4

ER -